On March 16, 2020, the SEC filed a complaint in the U.S. District Court for the Southern District of New York against AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), alleging that it violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The complaint alleges that AcelRx and Tetraphase Pharmaceuticals violated the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and that AcelRx and Tetraphase violated the antifraud provision of Section 10(b) and Rule 10b-5 thereunder of the Exchange Act.  The complaint further alleges that AcelRx violated Section 10(b) of the Exchange Act.  The complaint charges AcelRx and Tetraphase with violating Section 10(b) of the Exchange Act, Rule 10b-5 thereunder, and Sections 206(1), 206(2), and 206(4) of the Exchange Act and Rule 206(4)-8 thereunder.  Without admitting or denying the allegations in the complaint, AcelRx and Tetraphase consented to the entry of a final judgment that permanently enjoins them from violating the Exchange Act and Rule 10b-5.  The settlement is subject to court approval.  The SEC's complaint charges AcelRx with violations of Section 10(b) of Exchange Act Rule 10b-5.  The complaint seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's investigation was conducted by Raffi Asadorian and supervised by Chris Howerton and Ed Arce of the SEC's Philadelphia Regional Office.  The litigation will be led by Ms. Asadorian and Ms. Asadorian.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.